StockNews.com Initiates Coverage on Avinger (NASDAQ:AVGR)

Equities researchers at StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGR) in a research note issued on Friday. The firm set a “hold” rating on the medical device company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Avinger in a research report on Thursday, March 21st.

Avinger Stock Performance

Shares of NASDAQ:AVGR opened at $3.86 on Friday. The business has a fifty day moving average of $3.47 and a 200-day moving average of $3.25. Avinger has a twelve month low of $2.50 and a twelve month high of $18.00. The firm has a market cap of $6.11 million, a PE ratio of -0.15 and a beta of 1.22.

Avinger (NASDAQ:AVGR) last issued its quarterly earnings results on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by ($4.57). The firm had revenue of $1.91 million during the quarter, compared to analyst estimates of $2.52 million. On average, analysts anticipate that Avinger will post -2.08 EPS for the current fiscal year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.